JPWO2021214253A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021214253A5 JPWO2021214253A5 JP2022564300A JP2022564300A JPWO2021214253A5 JP WO2021214253 A5 JPWO2021214253 A5 JP WO2021214253A5 JP 2022564300 A JP2022564300 A JP 2022564300A JP 2022564300 A JP2022564300 A JP 2022564300A JP WO2021214253 A5 JPWO2021214253 A5 JP WO2021214253A5
- Authority
- JP
- Japan
- Prior art keywords
- azd9833
- cancer
- administered
- dose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WDHOIABIERMLGY-CMJOXMDJSA-N N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine Chemical compound FCCCN1CC(C1)NC=1C=NC(=CC=1)[C@H]1N([C@@H](CC2=C3C(=CC=C12)NN=C3)C)CC(F)(F)F WDHOIABIERMLGY-CMJOXMDJSA-N 0.000 claims description 65
- 229940125815 AZD9833 Drugs 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229960004390 palbociclib Drugs 0.000 claims description 4
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 claims description 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 229950001573 abemaciclib Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 238000009104 chemotherapy regimen Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009261 endocrine therapy Methods 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 229950003687 ribociclib Drugs 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 229950007127 trilaciclib Drugs 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- -1 relociclib Chemical compound 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014914P | 2020-04-24 | 2020-04-24 | |
| US63/014,914 | 2020-04-24 | ||
| PCT/EP2021/060589 WO2021214253A1 (fr) | 2020-04-24 | 2021-04-22 | Schéma posologique pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522415A JP2023522415A (ja) | 2023-05-30 |
| JPWO2021214253A5 true JPWO2021214253A5 (fr) | 2024-04-26 |
Family
ID=75728802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564300A Pending JP2023522415A (ja) | 2020-04-24 | 2021-04-22 | 癌の治療のための投薬レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210330653A1 (fr) |
| EP (1) | EP4138834A1 (fr) |
| JP (1) | JP2023522415A (fr) |
| KR (1) | KR20230005269A (fr) |
| CN (1) | CN115443135A (fr) |
| AU (1) | AU2021260829B2 (fr) |
| BR (1) | BR112022021141A2 (fr) |
| CA (1) | CA3179907A1 (fr) |
| IL (1) | IL297216A (fr) |
| MX (1) | MX2022013391A (fr) |
| TW (1) | TW202206073A (fr) |
| WO (1) | WO2021214253A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024083716A1 (fr) * | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinaisons d'un serd pour le traitement du cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03547B (fr) * | 2016-10-24 | 2020-07-20 | Astrazeneca Ab | Dérivés de 6,7,8,9-tétrahydro-3h-pyrazolo[4,3-f]isoquinoline utiles dans le traitement du cancer |
-
2021
- 2021-04-22 AU AU2021260829A patent/AU2021260829B2/en active Active
- 2021-04-22 CN CN202180030426.XA patent/CN115443135A/zh active Pending
- 2021-04-22 EP EP21722137.3A patent/EP4138834A1/fr active Pending
- 2021-04-22 JP JP2022564300A patent/JP2023522415A/ja active Pending
- 2021-04-22 US US17/237,112 patent/US20210330653A1/en not_active Abandoned
- 2021-04-22 MX MX2022013391A patent/MX2022013391A/es unknown
- 2021-04-22 CA CA3179907A patent/CA3179907A1/fr active Pending
- 2021-04-22 BR BR112022021141A patent/BR112022021141A2/pt unknown
- 2021-04-22 IL IL297216A patent/IL297216A/en unknown
- 2021-04-22 KR KR1020227040915A patent/KR20230005269A/ko active Search and Examination
- 2021-04-22 WO PCT/EP2021/060589 patent/WO2021214253A1/fr active Application Filing
- 2021-04-23 TW TW110114699A patent/TW202206073A/zh unknown
-
2023
- 2023-01-10 US US18/152,255 patent/US20230248709A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (fr) | ||
| AU2015301097B2 (en) | Drug combinations to treat multiple myeloma | |
| WO2018005695A1 (fr) | Utilisation d'antagonistes de neurokinine-1 dans le traitement d'une variété d'états pruritiques | |
| JP7278331B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| KR102319078B1 (ko) | 궤양성 대장염의 치료용 의약 조성물 | |
| JP2015528501A5 (fr) | ||
| JP2019508476A5 (fr) | ||
| Konopka-Filippow et al. | Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience | |
| JP2016505050A5 (fr) | ||
| TW201817425A (zh) | 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法 | |
| JP2004525143A5 (fr) | ||
| TWI783921B (zh) | 手部溼疹之治療 | |
| WO2017148129A1 (fr) | Composition pharmaceutique destinée au traitement de la cachexie et son utilisation | |
| JPWO2021214253A5 (fr) | ||
| JPWO2020257671A5 (fr) | ||
| JP2019001830A (ja) | 医薬 | |
| US11648235B1 (en) | Treatment of glioblastoma | |
| EP4110326B1 (fr) | Combinaison comprenant de l'alpélisib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique | |
| TWI841027B (zh) | 手部溼疹之治療 | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| JP2022177119A5 (fr) | ||
| WO2024104561A1 (fr) | Combinaisons thérapeutiques de capivasertib et de vénétoclax | |
| WO2023281413A1 (fr) | Méthodes et schémas posologiques comprenant pf-06873600 pour le traitement du cancer | |
| JP2022138369A (ja) | 間質性肺炎の治療剤 | |
| CN117357533A (zh) | 富马酸奥比特嗪与替莫唑胺联合用药在治疗脑胶质瘤中的应用 |